Neovascular age-related macular degeneration Trials in Campbell, United States
Conditions / Neovascular age-related macular degeneration / Campbell, United States
Neovascular age-related macular degeneration is a medical condition with active clinical research programs worldwide.
11 total trials for this combination
Showing top 10 of 11 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT00964795 | Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular (Wet) Age-related Macular Degeneration (AMD) | COMPLETED | PHASE3 |
| NCT03577899 | Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1) | TERMINATED | PHASE3 |
| NCT04777201 | A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration | COMPLETED | PHASE3 |
| NCT04704921 | Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD | RECRUITING | PHASE2/PHASE3 |
| NCT04684394 | A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration | TERMINATED | PHASE2 |
| NCT04757610 | OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) | TERMINATED | PHASE3 |
| NCT03834753 | A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) | COMPLETED | PHASE3 |
| NCT04864834 | Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration | COMPLETED | PHASE3 |
| NCT07007065 | Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) | RECRUITING | — |
| NCT04480463 | A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD) | COMPLETED | PHASE3 |